Dupixent 300 mg solution for injection in pre-filled pen

DRUG4 trials

Sponsors

Centre Hospitalier Universitaire De Nantes, Amsterdam UMC, Regeneron Pharmaceuticals Inc., Medical University Of Vienna

Conditions

Atopic DermatitisChronic rhinosinusitis with nasal polypsChronic rhinosinusitis without nasal polypsatopic dermatitischronic rhinosinusitis with nasal polypseosinophilic otitis media

Phase 3

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis.

Active, not recruitingCTIS2023-509425-53-00

Regeneron Pharmaceuticals Inc.Atopic Dermatitis

Start: 2015-11-09Target: 201Updated: 2025-11-04

Phase 4

Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

Active, not recruitingCTIS2022-501179-23-00

Centre Hospitalier Universitaire De Nantesatopic dermatitis

Start: 2023-03-08Target: 256Updated: 2025-07-11

Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study

RecruitingCTIS2023-509815-10-00

Medical University Of ViennaChronic rhinosinusitis with nasal polyps, Chronic rhinosinusitis without nasal polyps

Start: 2024-05-15Target: 80Updated: 2024-05-06

Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media

RecruitingCTIS2023-508068-31-00

Amsterdam UMCchronic rhinosinusitis with nasal polyps, eosinophilic otitis media

Start: 2024-09-11Target: 50Updated: 2024-08-19

Related Papers

Dupilumab step-down strategy to maintain remission in adult and adolescent patients with atopic dermatitis: study protocol for a non-inferiority randomized trial (MADULO).

2025-12-05